If you have been reading about lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-19. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
=== Microneedle Patches to Deliver Drugs === Drugs are delivered via scratch size patches known as Microneedle Patches. Microneedle patches are an invention of the introduction of drugs into the skin with the help of minute needles that are not painful. The patches can deliver vaccines or medications, including insulin to diabetes patients into the blood or skin (Reinke et al., 2024). They are easy to use and they could make people give treatments at home. However, such patches are very expensive and not easily accessible.
== Funding == ICICI Venture invested 35 crore in Metropolis in the year 2006 through its India Advantage Fund. In 2010, Warburg Pincus invested about $85 Million in Metropolis, paving a way for ICICI to exit. The Shah family purchased the exiting stake from Warburg Pincus for a healthy return on investment. The company is backed by several investors including Carlyle Group, CA Lotus Investments and Kohlberg Kravis Roberts (KKR). In 2015, KKR backed Ameera Shah through ₹5.6 billion (equivalent to ₹9.2 billion or US$96 million in 2026) promoter debt funding. In April 2019, the company raised Rs 530 crore from 26 anchor investors, including Small Cap World Fund, Neuberger Berman Emerging Market Equity Fund, Fundsmith Emerging Equities Trust PLC and First State Indian Sub Continent Fund, among others.
Combinatorial split-mix (split and pool) synthesis is based on the solid-phase synthesis developed by Merrifield. If a combinatorial peptide library is synthesized using 20 amino acids (or other kinds of building blocks), the bead form solid support is divided into 20 equal portions. This is followed by coupling a different amino acid to each portion. The third step is the mixing of all portions. These three steps comprise a cycle. Elongation of the peptide chains can be realized by simply repeating the steps of the cycle.
These are made especially problematic due to the chemical solvents' ability to extract far greater amounts of the potentially toxic compounds than water. In the context of these concerns, the World Health Organization advises against the consumption of ethanolic and acetonic kavalactone extracts, and says that "products should be developed from water-based suspensions of kava". The government of Australia prohibits the sales of such kavalactone extracts, and only permits the sale of kava products in their natural form or produced with cold water.
Sources: en.wikipedia.org
== Operations == Glenmark operates manufacturing facilities in India, the United States, Argentina, and the Czech Republic. Its oldest plant, in Maharashtra, opened in 1983. Other Indian sites are in Himachal Pradesh, Goa, Madhya Pradesh, and Sikkim. The company also runs a facility in Pilar, Argentina, focused on oncology injectables, and a plant in the Czech Republic acquired through the 2007 purchase of Medicamenta. U.S. corporate offices are in Elmwood Park, New Jersey. The Monroe, North Carolina plant, opened in 2018, is Glenmark's sole U.S. manufacturing site. In August 2021 the company recalled all products made there. The FDA identified 17 manufacturing deficiencies and issued a warning letter in 2022. After corrective actions, a December 2025 inspection was classified as Voluntary Action Indicated, allowing manufacturing to resume. Several Indian facilities have also drawn FDA citations. Good manufacturing practice violations brought a warning letter to the Himachal Pradesh plant in October 2019. The Goa facility was cited in November 2022 for inadequate procedures to verify product strength and purity. A July 2025 warning letter cited the Madhya Pradesh plant for deficiencies in cleaning and testing procedures.
=== Injections and implants === In 1933 or 1934, Schering introduced progesterone in oil solution as a medication by intramuscular injection under the brand name Proluton. This was the first pharmaceutical formulation of progesterone to be marketed for medical use. It was initially a corpus luteum extract, becoming pure synthesized progesterone only subsequently. A clinical study of the formulation was published in 1933. Multiple formulations of progesterone in oil solution for intramuscular injection, under the brand names Proluton, Progestin, and Gestone, were available by 1936. A parenteral route was used because oral progesterone had very low activity and was thought to be inactive. Progesterone was initially very expensive due to the large doses required. However, with the start of steroid manufacturing from diosgenin in the 1940s, costs greatly decreased. Subcutaneous pellet implants of progesterone were first studied in women in the late 1930s. They were the first long-acting progestogen formulation. Pellets were reported to be extruded out of the skin within a few weeks at high rates, even when implanted beneath the deep fascia, and also produced frequent inflammatory reactions at the site of implantation. In addition, they were absorbed too slowly and achieved unsatisfactorily low progesterone levels. Consequently, they were soon abandoned, in favor of other preparations such as aqueous suspensions.
In 1950, a 21 SAS squadron was raised to fight in the Korean War. After three months of training in Britain, it was informed that the squadron would no longer be required in Korea and so it instead volunteered to fight in the Malayan Emergency. Upon arrival in Malaya, it came under the command of Mike "Mad Mike" Calvert who was forming a new unit called the Malayan Scouts (SAS). Calvert had already formed one squadron from 100 volunteers in the Far East, which became A Squadron; the 21 SAS squadron then became B Squadron; and after a recruitment visit to Rhodesia by Calvert, C Squadron was formed from 100 Rhodesian volunteers. The Rhodesians returned home after three years' service and were replaced by a New Zealand squadron. By this time the need for a regular army SAS regiment had been recognised; the 22 SAS Regiment was formally added to the army list in 1952 and has been based at Hereford since 1960. In 1959 the third regiment, the 23 SAS Regiment, was formed by renaming the Reserve Reconnaissance Unit, which had succeeded MI9 and whose members were experts in escape and evasion.
Battelli MG, Lorenzoni E (1982). "Purification and properties of a new glutathione-dependent thiol:disulphide oxidoreductase from rat liver". Biochem. J. 207 (1): 133–8. doi:10.1042/bj2070133. PMC 1153833. PMID 6960894.
Advertisements were a large influence in the marketable appeal of skin whitening in China and Taiwan. Skincare products that are recognized to protect the skin included chemicals that assist in skin whitening. These products were marketed and promoted as the solution to appearing young forever. Skincare products have been predominantly created to serve as anti-aging to women in China and Taiwan of all ages.
Sources: en.wikipedia.org
=== Prior experiments === From the earliest days of radio technology, signals had been used for navigation using the radio direction finding (RDF) technique. RDF can determine the bearing to a radio transmitter, and several such measurements can be combined to produce a radio fix, allowing the receiver's position to be calculated. Given some basic changes to the broadcast signal, it was possible for the receiver to determine its location using a single station. The UK pioneered one such service in the form of the Orfordness Beacon. Through the early period of radio development it was widely known that certain materials, especially metal, reflected radio signals. This led to the possibility of determining the location of objects by broadcasting a signal and then using RDF to measure the bearing of any reflections. Such a system saw patents issued to Germany's Christian Hülsmeyer in 1904, and widespread experimentation with the basic concept was carried out from then on. These systems revealed only the bearing to the target, not the range, and due to the low power of radio equipment of that era, they were useful only for short-range detection. This led to their use for iceberg and collision warning in fog or bad weather, where all that was required was the rough bearing of nearby objects. The use of radio detection specifically against aircraft was first considered in the early 1930s. Teams in the UK, US, Japan, Germany and others had all considered this concept and put at least some amount of effort into developing it.
=== Psychic phenomena === Reviewing Georges Charpak and Henri Broch's Debunked! ESP, Telekenesis and Other Pseudoscience, he wrote "Charpak and Broch have done a fine job sweeping out the moneypchangers from the temple of science and exposing their tricks." He went on: "The hypothesis that paranormal phenomena are real but lie outside the limits of science is supported by a great mass of evidence.. ... I find it plausible that a world of mental phenomena should exist, too fluid and evanescent to be grasped by the cumbersome tools of science. ... I am suggesting that paranormal mental abilities and scientific method may be complementary. The word 'complementarity' is a technical term introduced into physics by Niels Bohr. It means that two descriptions of nature may both be valid but cannot be observed simultaneously. The classic example of complemntarity is the dual nature of light. In one experiment light is seen to behave as a continuous wave, in another experiment it behaves as a swarm of particles, but we cannot see the wave and the particles in the same experiment. Complementarity in physics is an established fact. The extension of the idea of complementarity to mental phenomena is pure speculation. But I find it plausible." He wrote a foreword to Elizabeth Lloyd Mayer's Extraordinary Knowing, arguing "ESP is real... but cannot be tested with the clumsy tools of science".
== Initial investigations == Concerns about an increase in infant collapses and deaths in the neonatal unit at the Countess of Chester Hospital first arose in June 2015, when four collapses occurred, three of them fatal. The unit normally recorded two or three deaths a year. The unit manager, Eirian Powell, and unit lead clinician Brearey carried out an informal review and reported the incidents to the trust's serious‑incident committee, which classified the deaths as medication errors. Brearey noted that Letby had been on duty for each incident but regarded this as an unsurprising coincidence, given staffing levels. He later told the statutory inquiry that no concerns had been raised about her practice at the time. Subsequent reporting in 2023 indicated that he had developed suspicions earlier and believed the trust failed to act on them. A Care Quality Commission inspection in February 2016 heard concerns about difficulties raising issues with managers but was not informed of an elevated mortality rate. Its report highlighted staffing and skill‑mix problems but described a generally positive organisational culture. In May 2016, the trust's executive team concluded that the rise in deaths was coincidental. National MBRRACE‑UK data later showed that the unit's neonatal death rate between June 2015 and June 2016 was at least 10 per cent higher than expected, with deaths in 2015 double those of the previous year. On 24 June 2016, following two further deaths, Brearey asked the duty executive to remove Letby from clinical duties, but was told she was safe to work.
=== Discovery === In the 1950s, a working group at the University of Pittsburgh conducted research on bacteria of the genus Lactobacillus, which require biotin as a growth factor. It has previously been shown that biotin is no longer necessary for the growth of bacteria if certain fatty acids are present in the culture medium instead. When investigating the influence of biotin on fatty acid metabolism, the researchers initially concentrated on the species L. arabinosus, which according to current systematics is classified as L. plantarum is carried out. They cultivated the bacteria in a semi-synthetic culture medium, harvested the cells and extracted the "free" lipids with acetone and diethyl ether. This fraction makes up about 20% of the total lipids. To obtain the "bound" lipids, an acid hydrolysis was then carried out, in which fatty acids bound as esters were released and also extracted with diethyl ether. The fatty acids were methylated with diazomethane to the methyl esters and separated according to their boiling points using fractional distillation. Based on the distillation curve, the presence of esters of C16, C18 and C19 fatty acids was expected. The fatty acid obtained from the C19 fraction showed a melting point at 28-29 °C after purification by recrystallization. The compound was investigated using numerous physical and chemical methods and its molecular formula was determined as C19H36O2. In 1950, this was only the second fatty acid with 19 carbon atoms to be isolated from microorganisms.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.